{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:19:14Z","timestamp":1783487954365,"version":"3.55.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cancer of unknown primary (CUP) represents a heterogeneous group of metastatic malignancies in which the primary site remains unidentified despite comprehensive clinical, laboratory, radiological, and pathological evaluation. CUP is generally characterized by aggressive biological behavior, poor prognosis, and the absence of standardized treatment strategies. Tumor-associated blood eosinophilia (TABE) is relatively uncommon and typically occurs after tumor dissemination, often indicating an unfavorable prognosis. SMARCB1 (INI-1) is a core subunit of the switch\/sucrose non-fermentable (SWI\/SNF) chromatin remodeling complex, and its functional loss can drive tumorigenesis through epigenetic dysregulation. However, cases of SMARCB1-deficient carcinoma presenting as CUP with marked TABE are exceedingly rare, posing significant diagnostic and therapeutic challenges.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>A 71-year-old man presented with a painless mass in the left side of the neck accompanied by generalized pruritus. Laboratory evaluation revealed persistent peripheral blood eosinophilia, and imaging studies demonstrated multiple enlarged lymph nodes in the left supraclavicular region and abdominal cavity. Histopathological examination of a lymph node biopsy showed poorly differentiated carcinoma. Immunohistochemistry revealed loss of nuclear SMARCB1 expression. A final diagnosis of SMARCB1-deficient undifferentiated carcinoma was established, and comprehensive systemic evaluation failed to identify a primary tumor. The patient received paclitaxel combined with cisplatin and a programmed cell death protein 1 (PD-1) inhibitor. Immunotherapy was discontinued due to the development of immune-related cutaneous adverse events. Despite subsequent management, the disease progressed rapidly, with the development of brainstem metastasis, and the patient ultimately died.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We report a case of SMARCB1-deficient undifferentiated carcinoma presenting as CUP, predominantly with cervical lymph node metastases, accompanied by marked TABE. The benefit of current empirical treatment strategies appears limited. Future prospective clinical studies targeting the epigenetic vulnerabilities of this entity are warranted to improve patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1853027","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:52:09Z","timestamp":1783486329000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["SMARCB1 (INI-1)-deficient carcinoma with eosinophilia and cervical lymph node metastasis of unknown primary: a case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Lei","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Geriatrics, The Second Affiliated Hospital of Jiaxing University","place":["Jiaxing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, The Second Affiliated Hospital of Jiaxing University","place":["Jiaxing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-song","family":"He","sequence":"additional","affiliation":[{"name":"Department of Central Laboratory, The Second Affiliated Hospital of Jiaxing University","place":["Jiaxing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Second Affiliated Hospital of Jiaxing University","place":["Jiaxing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-juan","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Second Affiliated Hospital of Jiaxing University","place":["Jiaxing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-tao","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Ultrasonography, The Second Affiliated Hospital of Jiaxing University","place":["Jiaxing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Affiliated Hospital of Jiaxing University","place":["Jiaxing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen-fen","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, The Second Affiliated Hospital of Jiaxing University","place":["Jiaxing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"B1","article-title":"Cancer of unknown primary site","volume":"393","author":"Bellanti","year":"2025","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"104297","DOI":"10.1016\/j.critrevonc.2024.104297","article-title":"Cancer of unknown primary and the \u00abseed and soil\u00bb hypothesis","volume":"196","author":"Zolotykh","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.3390\/ijms24065588","article-title":"From biology to diagnosis and treatment: The Ariadne's thread in cancer of unknown primary","volume":"24","author":"Mathew","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01060-8","article-title":"Rethinking cancer of unknown primary: from diagnostic challenge to targeted treatment","volume":"22","author":"Pouyiourou","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00814-6","article-title":"Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study","volume":"404","author":"Kr\u00e4mer","year":"2024","journal-title":"Lancet (London England)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e004822","DOI":"10.1136\/jitc-2022-004822","article-title":"Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial","volume":"10","author":"Raghav","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.009","article-title":"Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary","volume":"33","author":"Tanizaki","year":"2021","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00520-4","article-title":"Eosinophilic dermatoses: Recognition and management","volume":"21","author":"Marzano","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2018.1.326","article-title":"Hypereosinophilic syndrome: approach to treatment in the era of precision medicine","volume":"2018","author":"Klion","year":"2018","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2255-4","article-title":"Opposing roles of eosinophils in cancer","volume":"68","author":"Simon","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.3390\/cancers14133285","article-title":"SMARCB1 (INI-1)-deficient sinonasal carcinoma: A systematic review and pooled analysis of treatment outcomes","volume":"14","author":"Lee","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-17-0151","article-title":"Powering precision medicine through an international consortium","volume":"7","year":"2017","journal-title":"Cancer Discov"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.3390\/cancers14153645","article-title":"SMARCB1-deficient cancers: Novel molecular insights and therapeutic vulnerabilities","volume":"14","author":"Cooper","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3390\/cancers13030451","article-title":"Cancer of unknown primary: Challenges and progress in clinical management","volume":"13","author":"Laprovitera","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/nejmcp2402691","article-title":"Cancer of unknown primary site","volume":"392","author":"Raghav","year":"2025","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03073-7","article-title":"Cancer of unknown primary: the hunt for its elusive tissue-of-origin - is it time to call off the search","volume":"133","author":"Spurgeon","year":"2025","journal-title":"Br J Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2023.0168","article-title":"New era: prospects for managing cancer of unknown primary","volume":"20","author":"Li","year":"2023","journal-title":"Cancer Biol Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.11.013","article-title":"Cancer of unknown primary: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Kr\u00e4mer","year":"2022","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2000.18.17.3101","article-title":"Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group study","volume":"18","author":"Briasoulis","year":"2000","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/bjc.2012.516","article-title":"Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis","volume":"108","author":"Lee","year":"2012","journal-title":"Br J Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13072-025-00590-w","article-title":"Chromatin remodeling and cancer: the critical influence of the SWI\/SNF complex","volume":"18","author":"Hao","year":"2025","journal-title":"Epigenet Chromatin"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-00978-5","article-title":"Chromatin remodellers as therapeutic targets","volume":"23","author":"Malone","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-024-09011-4","article-title":"Regulatory roles of SWI\/SNF chromatin remodeling complexes in immune response and inflammatory diseases","volume":"68","author":"Sun","year":"2024","journal-title":"Clin Rev Allergy Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2024.101313","article-title":"Treating human cancer by targeting EZH2","volume":"12","author":"Xu","year":"2024","journal-title":"Genes Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.5152\/ejra.2023.23092","article-title":"Molecular characterization of sinonasal undifferentiated carcinoma\u2014past, present, and future","volume":"6","author":"Takahashi","year":"2023","journal-title":"Eur J Rhinol Allergy"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103398","article-title":"Safety and efficacy of HH2853, a novel EZH1\/2 dual inhibitor, in patients with refractory solid tumours or non-Hodgkin lymphomas: a phase I study","volume":"86","author":"Fan","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.s289544","article-title":"Current and emerging therapeutic approaches for extracranial Malignant rhabdoid tumors","volume":"14","author":"Nemes","year":"2022","journal-title":"Cancer Manag Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac151","article-title":"Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid\/rhabdoid tumor","volume":"25","author":"Upadhyaya","year":"2023","journal-title":"Neuro-oncology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1186\/s12967-023-04418-7","article-title":"Eosinophils in the tumor microenvironment: implications for cancer immunotherapy","volume":"21","author":"Ghaffari","year":"2023","journal-title":"J Transl Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/gidisord7040074","article-title":"Paraneoplastic hypereosinophilia revealing disseminated colorectal signet ring cell carcinoma","volume":"7","author":"Rink","year":"2025","journal-title":"Gastrointestinal Disord"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.20944\/preprints202508.0641.v1","article-title":"Eosinophil ETosis and cancer: Ultrastructural evidence and oncological implications","volume":"17","author":"Caruso","year":"2025","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1853027\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:52:25Z","timestamp":1783486345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1853027\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":31,"alternative-id":["10.3389\/fonc.2026.1853027"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1853027","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"article-number":"1853027"}}